- Home
- JILL vs TLSI Comparison
JILL vs TLSI Comparison
Compare JILL & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JILL | TLSI |
|---|---|---|
| Founded | 1959 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.1M | 244.3M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | JILL | TLSI |
|---|---|---|
| Price | $14.49 | $7.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $18.75 | $10.67 |
| AVG Volume (30 Days) | 73.0K | ★ 154.3K |
| Earning Date | 12-10-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $600,981,000.00 | $40,207,000.00 |
| Revenue This Year | $0.87 | $55.06 |
| Revenue Next Year | $2.44 | $46.04 |
| P/E Ratio | $6.50 | ★ N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $13.32 | $3.42 |
| 52 Week High | $30.40 | $7.33 |
Technical Indicators
Market Signals| Indicator | JILL | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 40.71 | 72.14 |
| Support Level | $16.04 | $6.06 |
| Resistance Level | $16.75 | $7.27 |
| Average True Range (ATR) | 0.70 | 0.61 |
| MACD | 0.08 | 0.12 |
| Stochastic Oscillator | 19.36 | 96.06 |
Price Performance
Historical ComparisonAbout JILL J. Jill Inc.
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). Revenue is derived from the sale of apparel and accessory merchandise through the company's Retail and Direct channels, which include website and catalog phone orders. Revenue also includes shipping and handling fees collected from customers.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.